Monopar Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q2 2024 | 2 | -$1.72 | -$1.32 | -$1.52 |
| Q3 2024 | 1 | -$1.52 | -$1.52 | -$1.52 |
| Q1 2025 | 1 | -$1.79 | -$1.79 | -$1.79 |
| Q2 2025 | 1 | -$1.85 | -$1.85 | -$1.85 |
| Q3 2025 | 1 | -$1.92 | -$1.92 | -$1.92 |
| Q4 2025 | 1 | -$1.54 | -$1.54 | -$1.54 |
Monopar Therapeutics Inc. Earnings Date And Information
Monopar Therapeutics Inc. last posted its earnings results on Friday, August 9th, 2024. The company reported $-0.5 earnings per share for the quarter, missing analysts' consensus estimates of $-0.45 by $0.05. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Monopar Therapeutics Inc. has generated $-3 earnings per share over the last year ($-3.04 diluted earnings per share) and currently has a price-to-earnings ratio of -7.74. Monopar Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Monopar Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/09/2024 | Q2 2024 | -$0.45 | -$0.49 | -0.04 | $0 | $0 |
| 05/09/2024 | Q1 2024 | -$0.85 | -$0.10 | 0.75 | $0 | |
| 03/28/2024 | Q4 2023 | -$0.85 | -$0.12 | 0.73 | $0 | |
| 11/09/2023 | Q3 2023 | -$0.95 | -$0.14 | 0.81 | $0 | |
| 08/10/2023 | Q2 2023 | -$0.95 | -$0.16 | 0.79 | $0 | |
| 05/11/2023 | Q1 2023 | -$1.00 | -$0.18 | 0.82 | $0 | |
| 03/23/2023 | Q4 2022 | -$1.05 | -$0.22 | 0.83 | $0 | |
| 11/10/2022 | Q3 2022 | -$1.15 | -$0.19 | 0.96 | $0 | |
| 08/11/2022 | Q2 2022 | -$1.05 | -$0.22 | 0.83 | $0 | |
| 05/12/2022 | Q1 2022 | -$1.20 | -$0.19 | 1.01 | $0 | |
| 03/24/2022 | Q4 2021 | -$0.90 | -$0.21 | 0.69 | $0 | |
| 11/12/2021 | Q3 2021 | -$1.10 | -$0.20 | 0.9 | $0 | |
| 08/12/2021 | Q2 2021 | -$1.05 | -$0.17 | 0.88 | $0 | |
| 05/13/2021 | Q1 2021 | -$1.10 | -$0.16 | 0.94 | $0 | |
| 03/25/2021 | Q4 2020 | -$0.75 | -$0.19 | 0.56 | $0 | |
| 11/12/2020 | Q3 2020 | -$0.75 | -$0.15 | 0.6 | $0 | |
| 08/06/2020 | Q2 2020 | -$1.25 | -$0.14 | 1.11 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.11 | -$0.10 | 0.01 | $0 | |
| 03/27/2020 | Q4 2019 | -$0.07 | -$0.11 | -0.04 | $0 | |
| 11/12/2019 | Q3 2019 | -$0.07 | $0 |
Monopar Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Monopar Therapeutics Inc.'s earnings date?
Monopar Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
How can I listen to Monopar Therapeutics Inc.'s earnings conference call?
The conference call for Monopar Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Monopar Therapeutics Inc.'s conference call transcript?
The conference call transcript for Monopar Therapeutics Inc.'s latest earnings report can be read online.
-
How much profit does Monopar Therapeutics Inc. generate each year?
Monopar Therapeutics Inc. (:MNPR) has a recorded net income of $0. Monopar Therapeutics Inc. has generated $-3.04 earnings per share over the last four quarters.
-
What is Monopar Therapeutics Inc.'s price-to-earnings ratio?
Monopar Therapeutics Inc. (:MNPR) has a price-to-earnings ratio of -7.74 and price/earnings-to-growth ratio is 0.12.
